Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a rare, neonatally lethal lung developmental disorder characterized by severe respiratory distress, persistent pulmonary hypertension, and refractory hypoxemia unresponsive to therapy. Affected infants uniformly die within the first month of life without lung transplant ([PMID:19500772]).
Heterozygous FOXF1 variants cause ACD/MPV in an autosomal dominant manner with evidence of paternal imprinting. Over 90 unrelated probands harbor de novo nonsense, frameshift, missense, no-stop, and enhancer copy‐number variants in FOXF1 ([PMID:23505205]), and familial segregation in four pedigrees—including one with five of six siblings affected—confirms transmission and imprinting effects ([PMID:22990143]).
The variant spectrum includes 38 novel nonsynonymous changes: nine nonsense, seven frameshift, one in‐frame deletion, 20 missense, and one no-stop mutation; recurrent hotspot c.691_698del (p.Ala231ArgfsTer61) has been reported in three unrelated families ([PMID:23505205]; [PMID:31436901]). Deep intronic deletions and enhancer CNVs reduce FOXF1 transcript levels by ~40% and disrupt enhancer activity in lung fibroblasts ([PMID:23943206]).
Functional studies demonstrate that FOXF1 haploinsufficiency impairs vascular development via loss of endothelial FOXF1. Endothelial‐specific Foxf1 knockout mice recapitulate ACD/MPV features, showing reduced proliferation, increased apoptosis, and downregulation of VEGF receptors FLT1/FLK1, PECAM1, PDGFB, and integrin β3 ([PMID:25091710]). The S52F FOXF1 mutation disrupts STAT3 binding, inhibits angiogenic signaling, and nanoparticle delivery of STAT3 cDNA rescues lung angiogenesis in knock‐in mice ([PMID:31199666]).
Non‐coding SNVs in the lung‐specific FOXF1 enhancer can mitigate or rescue the ACD/MPV phenotype by acting as hypermorphs or by modifying allele‐specific expression; a regulatory SNV rs560517434-A increased promoter activity 10‐fold in vitro and correlates with survival in a four‐generation family ([PMID:35902696]). Deep parental mosaicism for enhancer deletions underscores variable penetrance and high recurrence risk ([PMID:36124617]).
No studies to date have refuted the FOXF1–ACD/MPV association. The weight of genetic and experimental evidence meets ClinGen criteria for a definitive gene–disease relationship, supporting rapid, noninvasive FOXF1 testing in neonates with unexplained pulmonary hypertension.
Key Take-home: Early FOXF1 sequencing enables prompt diagnosis of ACD/MPV, informs prognostication, and guides clinical decision-making in critically ill neonates.
Gene–Disease AssociationDefinitive
Genetic EvidenceStrongOver 90 probands with heterozygous FOXF1 variants ([PMID:23505205]); familial segregation in 4 pedigrees with 5 affected sibs ([PMID:22990143]) Functional EvidenceStrongEndothelial‐specific Foxf1 knockout recapitulates ACD/MPV in mice; STAT3 nanoparticle rescue restores angiogenesis ([PMID:25091710]; [PMID:31199666]) |